Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial Post author:admin Post published: March 12, 2025 Post category:uncategorized NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. You Might Also Like New nanomaterial kills cancer cells via oxidative stress January 28, 2026 Proof-of-concept study holds promise for safer gene therapy techniques for treating immunodeficiencies November 1, 2023 New international guidelines highlight the extensive benefits of cardiac rehabilitation August 28, 2026
Proof-of-concept study holds promise for safer gene therapy techniques for treating immunodeficiencies November 1, 2023
New international guidelines highlight the extensive benefits of cardiac rehabilitation August 28, 2026